Skip Navigation LinksHome > December 2010 - Volume 29 - Issue 12 > Treatment of Ocular Graft-Versus-Host Disease With Topical C...
Cornea:
doi: 10.1097/ICO.0b013e3181e456f0
Clinical Science

Treatment of Ocular Graft-Versus-Host Disease With Topical Cyclosporine 0.05%

Malta, João Baptista MD*†; Soong, H Kaz MD*; Shtein, Roni M MD*; Musch, David C PhD, MPH*‡; Rhoades, William BS*; Sugar, Alan MD*; Mian, Shahzad I MD*

Collapse Box

Abstract

Purpose: To evaluate the efficacy of topical cyclosporine-A 0.05% (CsA) in the treatment of dry eye syndrome in ocular graft-versus-host disease after bone marrow transplantation (BMT) of hematopoietic stem cells.

Methods: One-hundred five patients were enrolled in a retrospective, comparative, interventional case series. Eighty-one patients received topical CsA starting 1 month before BMT (treatment group), and 24 patients did not receive CsA until at least 6 months after the transplantation (control group). Mean follow-up time was 17.5 ± 11.0 months (range: 6.0-49.0 months). Clinical history, ocular surface disease index questionnaire, slit-lamp examination, lissamine green and fluorescein staining of the ocular surface, tear breakup time, and Schirmer test with topical anesthesia were obtained to create a composite dry eye-grading score.

Results: Dry eye symptoms were significantly more severe in the control group at 3 months, 1 year, and 2 years (P < 0.05). There was no correlation with type of stem cell transplant (related vs. unrelated donor), presenting indication for BMT, or concurrent systemic immunosuppressive medications.

Conclusions: Pre-BMT initiation of topical CsA may reduce the inflammatory response in the lacrimal glands that may be responsible for the development of post-BMT keratitis sicca.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Readers Of this Article Also Read